Stempeutics Weighs Japan Tie-Up For Stem Cell Therapy
This article was originally published in PharmAsia News
Executive Summary
Japan continues to attract interest in the area of regenerative medicine, with Indian firm Stempeutics Research saying it is eyeing collaboration opportunities for its stem-cell based drug, Stempeucel, initially targeted for the treatment of critical limb ischemia.
You may also be interested in...
Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy
Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.